CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter provided the requested additional economic information. Please see the Bendamustine (Treanda) for Chronic Lymphocytic Leukemia (First Line) Details page for more information.
| Project Number | pCODR 10011 |
|---|---|
| Brand Name | Treanda |
| Generic Name | Bendamustine hydrochloride |
| Strength | 25mg/vial and 100mg/vial |
| Tumour Type | Leukemia |
| Indication | Chronic lymphocytic leukemia (Relapsed/ Refractory) |
| Funding Request | Patients with Chronic Lymphocytic Leukemia (relapsed/refractory) for whom fludarabine-based therapy is not appropriate |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | Yes |
| NOC Date | August 24, 2012 |
| Manufacturer | Lundbeck Canada Inc. |
| Sponsor | Lundbeck Canada Inc. |
| Clarification | As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter provided the requested additional economic information. Please see the Bendamustine (Treanda) for Chronic Lymphocytic Leukemia (First Line) Details page for more information. |
| Submission Date | April 24, 2012 |
| Submission Deemed Complete | May 1, 2012 |
| Submission Type | New Drug |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | May 8, 2012 |
| Check-point meeting | June 27, 2012 |
| pERC Meeting | September 20, 2012 |
| Initial Recommendation Issued | October 4, 2012 |
| Feedback Deadline ‡ | October 19, 2012 |
| pERC Reconsideration Meeting | November 15, 2012 |
| Final Recommendation Issued | November 29, 2012 |
| Notification to Implement Issued | December 14, 2012 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
